Veeva is a leader in the life sciences niche of the cloud computing industry.
The company’s recent launches, Vault AI and Veeva Falcon, may improve its clients’ workflows through AI agents.
Veeva’s deep switching costs and a credible $6 billion revenue target could allow it to beat the market over the next five years.
Software stocks have had a difficult go of it this year, as some investors fear that artificial intelligence (AI) will displace many of their services. However, some companies in the industry have bounced back. One of them is Veeva Systems (NYSE:VEEV). The stock lost significant value in the first half of the year, but over the past six months it has gained 81%. There may be more to come. In my view, Veeva Systems could beat the market through 2031. Here's why.
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Veeva Systems offers cloud-based solutions specifically tailored to the demands and constraints that life sciences companies face. This sector is unique enough that generic cloud solutions won't do. Some of the realities they face include a strict regulatory landscape, challenges in clinical trial management (including patient confidentiality and scientific rigor), difficulties managing relationships with healthcare professionals to make sales and marketing efforts as efficient as possible, and much more.
Veeva Systems addresses the industry's complex regulatory, clinical, and commercial requirements with specialized cloud applications. While this is a fairly small niche of the broader cloud industry, Veeva is one of the leaders in this market. It has attracted some of the largest and most successful life sciences companies, including pharmaceutical leaders such as Merck (NYSE:MRK) and Novo Nordisk (NYSE:NVO).
Could AI make the company's services obsolete? That's unlikely. Veeva Systems has adapted to the new world order by integrating AI-powered applications into the company's products. For instance, it launched Vault AI, which integrates AI agents into life sciences companies' workflows to boost productivity, and Veeva Falcon, an AI-powered platform designed to automate much of the life sciences workflow, potentially freeing up human labor to focus on other tasks.
Consider one possible application of Veeva Falcon. According to Veeva's CFO, Brian Van Wagener, certain regulatory inquiries that can take life sciences companies a month to respond to may be reduced to less than a week with Veeva Falcon. That's a massive difference which, at scale, could save companies significant amounts over the long run. So, Veeva's AI-related work looks promising for the future. In the meantime, the company continues to record excellent financial results.
In the second quarter of its fiscal year 2027, which ended July 31, Veeva Systems' revenue grew by 18% year over year to $928 million. The company's non-GAAP earnings per share were $2.35, up from the $1.99 reported in the year-ago period. Veeva beat expectations, sending the stock price soaring post-earnings.
Veeva Systems set a goal of achieving a $6 billion annual revenue run rate by the end of calendar year 2030 (most of that year will fall within its fiscal year 2031). The company has generated $3.5 billion in revenue over the trailing-12-month period, so it has some work to do to achieve its 2030 target, but it is on track to do so, according to management. It is also worth noting that the company has set similar medium-term targets in the past and has achieved them, sometimes ahead of schedule.
Further, the company also sees a $30 billion total addressable market (TAM) -- a number that has grown over the years. Suppose Veeva Systems ends the calendar year 2030 with a $6 billion annual revenue run rate and generates that much in sales in 2031. Given its current market cap of $48.5 billion, the company is trading at about 8x estimated 2031 sales.
That sounds high, but Veeva has historically commanded high valuation multiples for a reason: It is a leader in a growing niche of the large cloud market, boasts a wide moat from switching costs, and still has excellent long-term prospects. My view is that Veeva Systems is likely to achieve its 2030 goal, and, based on its TAM, it will be able to continue tapping into massive opportunities long after, so the market may continue to assign the stock high valuation multiples.
Veeva's current price-to-sales ratio is 14.5. If it can stay at roughly these levels while the company reaches $6 billion in revenue by 2031, its market cap could rise by 79.5% over this period, or about 12.4% annualized. In my view, Veeva Systems can pull that off, which makes it an excellent stock to buy today and hold onto through 2031.
Before you buy stock in Veeva Systems, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Veeva Systems wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $322,605!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $927,581!*
Now, it’s worth noting Stock Advisor’s total average return is 792% — a market-crushing outperformance compared to 202% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 19, 2026.
Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool has positions in and recommends Merck, Novo Nordisk, and Veeva Systems. The Motley Fool has a disclosure policy.